Does the media favor SEPN or XFOR?

In the previous week, Septerna had 17 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 33 mentions for Septerna and 16 mentions for X4 Pharmaceuticals. Septerna's average media sentiment score of 0.62 beat X4 Pharmaceuticals' score of 0.61 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 6 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive X4 Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IMCR or XFOR?

In the previous week, Immunocore and Immunocore both had 16 articles in the media. Immunocore's average media sentiment score of 0.73 beat X4 Pharmaceuticals' score of 0.61 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XFOR or RXRX?

In the previous week, X4 Pharmaceuticals had 5 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 16 mentions for X4 Pharmaceuticals and 11 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.62 beat X4 Pharmaceuticals' score of 0.61 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANAB or XFOR?

In the previous week, X4 Pharmaceuticals had 13 more articles in the media than AnaptysBio. MarketBeat recorded 16 mentions for X4 Pharmaceuticals and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.63 beat X4 Pharmaceuticals' score of 0.61 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XFOR or ZYME?

In the previous week, Zymeworks had 6 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 22 mentions for Zymeworks and 16 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.61 beat Zymeworks' score of 0.54 indicating that X4 Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

X4 Pharmaceuticals (XFOR) Competitors

$4.24 -0.05 (-1.07%)

As of 11:43 AM Eastern

Compare

XFOR vs. SEPN, IMCR, RXRX, ANAB, and ZYME

Should you buy X4 Pharmaceuticals stock or one of its competitors? X4 Pharmaceuticals's main competitors and comparable companies include Septerna (SEPN), Immunocore (IMCR), Recursion Pharmaceuticals (RXRX), AnaptysBio (ANAB), and Zymeworks (ZYME). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does X4 Pharmaceuticals compare to Septerna?

Septerna (NASDAQ:SEPN) and X4 Pharmaceuticals (NASDAQ:XFOR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Septerna has a net margin of -24.51% compared to X4 Pharmaceuticals' net margin of -568.80%. Septerna's return on equity of -9.59% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.59%	-6.22%
X4 Pharmaceuticals	-568.80%	-64.95%	-37.33%

Septerna has higher revenue and earnings than X4 Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	45.00	-$48.88M	-$0.54	N/A
X4 Pharmaceuticals	$35.11M	11.98	-$79.20M	-$1.20	N/A

In the previous week, Septerna had 17 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 33 mentions for Septerna and 16 mentions for X4 Pharmaceuticals. Septerna's average media sentiment score of 0.62 beat X4 Pharmaceuticals' score of 0.61 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	6 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
X4 Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

Septerna currently has a consensus target price of $51.33, indicating a potential upside of 15.89%. X4 Pharmaceuticals has a consensus target price of $11.25, indicating a potential upside of 165.08%. Given X4 Pharmaceuticals' higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 5.8% of Septerna shares are owned by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Septerna beats X4 Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Immunocore?

Immunocore (NASDAQ:IMCR) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Immunocore has a net margin of -4.20% compared to X4 Pharmaceuticals' net margin of -568.80%. Immunocore's return on equity of -4.54% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
X4 Pharmaceuticals	-568.80%	-64.95%	-37.33%

84.5% of Immunocore shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 10.1% of Immunocore shares are held by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Immunocore has higher revenue and earnings than X4 Pharmaceuticals. Immunocore is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	4.30	-$35.51M	-$0.37	N/A
X4 Pharmaceuticals	$35.11M	11.98	-$79.20M	-$1.20	N/A

Immunocore has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Immunocore currently has a consensus target price of $57.29, suggesting a potential upside of 69.23%. X4 Pharmaceuticals has a consensus target price of $11.25, suggesting a potential upside of 165.08%. Given X4 Pharmaceuticals' higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Immunocore and Immunocore both had 16 articles in the media. Immunocore's average media sentiment score of 0.73 beat X4 Pharmaceuticals' score of 0.61 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunocore beats X4 Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Recursion Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

X4 Pharmaceuticals presently has a consensus price target of $11.25, suggesting a potential upside of 165.08%. Recursion Pharmaceuticals has a consensus price target of $8.10, suggesting a potential upside of 155.92%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe X4 Pharmaceuticals is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

X4 Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

X4 Pharmaceuticals has a net margin of -568.80% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-64.95%	-37.33%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

X4 Pharmaceuticals has higher earnings, but lower revenue than Recursion Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	11.98	-$79.20M	-$1.20	N/A
Recursion Pharmaceuticals	$74.68M	22.46	-$644.76M	-$1.04	N/A

In the previous week, X4 Pharmaceuticals had 5 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 16 mentions for X4 Pharmaceuticals and 11 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.62 beat X4 Pharmaceuticals' score of 0.61 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Recursion Pharmaceuticals beats X4 Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

AnaptysBio has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

AnaptysBio has a net margin of -11.53% compared to X4 Pharmaceuticals' net margin of -568.80%. AnaptysBio's return on equity of 0.00% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
X4 Pharmaceuticals	-568.80%	-64.95%	-37.33%

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 31.5% of AnaptysBio shares are owned by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AnaptysBio presently has a consensus price target of $82.00, suggesting a potential upside of 43.16%. X4 Pharmaceuticals has a consensus price target of $11.25, suggesting a potential upside of 165.08%. Given X4 Pharmaceuticals' higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

AnaptysBio has higher revenue and earnings than X4 Pharmaceuticals. AnaptysBio is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	7.23	-$13.23M	-$1.08	N/A
X4 Pharmaceuticals	$35.11M	11.98	-$79.20M	-$1.20	N/A

In the previous week, X4 Pharmaceuticals had 13 more articles in the media than AnaptysBio. MarketBeat recorded 16 mentions for X4 Pharmaceuticals and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.63 beat X4 Pharmaceuticals' score of 0.61 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AnaptysBio beats X4 Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Zymeworks?

X4 Pharmaceuticals (NASDAQ:XFOR) and Zymeworks (NASDAQ:ZYME) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

X4 Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

X4 Pharmaceuticals currently has a consensus price target of $11.25, suggesting a potential upside of 165.08%. Zymeworks has a consensus price target of $40.75, suggesting a potential upside of 63.16%. Given X4 Pharmaceuticals' higher possible upside, research analysts clearly believe X4 Pharmaceuticals is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by company insiders. Comparatively, 33.5% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

X4 Pharmaceuticals has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	11.98	-$79.20M	-$1.20	N/A
Zymeworks	$105.96M	16.73	-$81.13M	-$2.02	N/A

Zymeworks has a net margin of -405.31% compared to X4 Pharmaceuticals' net margin of -568.80%. X4 Pharmaceuticals' return on equity of -64.95% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-64.95%	-37.33%
Zymeworks	-405.31%	-72.30%	-37.18%

In the previous week, Zymeworks had 6 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 22 mentions for Zymeworks and 16 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.61 beat Zymeworks' score of 0.54 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Zymeworks beats X4 Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get X4 Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XFOR vs. The Competition

Export

Metric	X4 Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$420.89M	$3.69B	$6.97B	$13.06B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-3.54	10.36	269.56	25.27
Price / Sales	11.98	1,288.04	596.64	100.41
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	1.99	17.39	13.00	6.30
Net Income	-$79.20M	-$13.32M	$3.45B	$347.83M
7 Day Performance	-8.53%	0.34%	0.57%	0.94%
1 Month Performance	5.57%	0.13%	1.22%	0.90%
1 Year Performance	35.16%	53.78%	66.67%	20.40%

X4 Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XFOR X4 Pharmaceuticals	1.8093 of 5 stars	$4.24 -1.1%	$11.25 +165.1%	+46.4%	$420.89M	$35.11M	N/A	80	News Coverage Earnings Report Analyst Downgrade Insider Trade Analyst Revision
SEPN Septerna	1.7495 of 5 stars	$38.85 +0.1%	$46.56 +19.8%	+286.1%	$1.75B	$45.95M	N/A	N/A	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
IMCR Immunocore	3.7636 of 5 stars	$33.98 -0.1%	$57.29 +68.6%	+3.6%	$1.73B	$400.02M	N/A	320	Trending News Analyst Revision
RXRX Recursion Pharmaceuticals	1.854 of 5 stars	$3.29 +2.2%	$8.10 +146.2%	-41.9%	$1.71B	$74.68M	N/A	400	Options Volume
ANAB AnaptysBio	2.26 of 5 stars	$55.47 -2.0%	$82.00 +47.8%	+170.4%	$1.68B	$234.60M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XFOR) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

X4 Pharmaceuticals (XFOR) Competitors

XFOR vs. SEPN, IMCR, RXRX, ANAB, and ZYME

How does X4 Pharmaceuticals compare to Septerna?

Summary

How does X4 Pharmaceuticals compare to Immunocore?

Summary

How does X4 Pharmaceuticals compare to Recursion Pharmaceuticals?

Summary

How does X4 Pharmaceuticals compare to AnaptysBio?

Summary

How does X4 Pharmaceuticals compare to Zymeworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR vs. The Competition

X4 Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

X4 Pharmaceuticals (XFOR) Competitors

XFOR vs. SEPN, IMCR, RXRX, ANAB, and ZYME

How does X4 Pharmaceuticals compare to Septerna?

Is SEPN or XFOR more profitable?

Which has preferable valuation and earnings, SEPN or XFOR?

Does the media favor SEPN or XFOR?

Which has more volatility and risk, SEPN or XFOR?

Do analysts prefer SEPN or XFOR?

Do insiders and institutionals believe in SEPN or XFOR?

Summary

How does X4 Pharmaceuticals compare to Immunocore?

Is IMCR or XFOR more profitable?

Do insiders and institutionals hold more shares of IMCR or XFOR?

Which has higher valuation & earnings, IMCR or XFOR?

Which has more volatility & risk, IMCR or XFOR?

Do analysts recommend IMCR or XFOR?

Does the media prefer IMCR or XFOR?

Summary

How does X4 Pharmaceuticals compare to Recursion Pharmaceuticals?

Do institutionals and insiders have more ownership in XFOR or RXRX?

Do analysts rate XFOR or RXRX?

Which has more volatility & risk, XFOR or RXRX?

Is XFOR or RXRX more profitable?

Which has stronger valuation and earnings, XFOR or RXRX?

Does the media favor XFOR or RXRX?

Summary

How does X4 Pharmaceuticals compare to AnaptysBio?

Which has more volatility and risk, ANAB or XFOR?

Is ANAB or XFOR more profitable?

Do institutionals & insiders hold more shares of ANAB or XFOR?

Do analysts rate ANAB or XFOR?

Which has stronger earnings and valuation, ANAB or XFOR?

Does the media prefer ANAB or XFOR?

Summary

How does X4 Pharmaceuticals compare to Zymeworks?

Which has more risk & volatility, XFOR or ZYME?

Do analysts prefer XFOR or ZYME?

Do insiders and institutionals believe in XFOR or ZYME?

Which has preferable valuation and earnings, XFOR or ZYME?

Is XFOR or ZYME more profitable?

Does the media favor XFOR or ZYME?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR vs. The Competition

X4 Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools